A recent study suggests that patients who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional lifestyle regimens.
Findings released in a major medical journal shows that while obese people frequently drop substantial amounts of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users buying these medications should be cognizant of the potential of fast rebound weight gain when the therapy is stopped," cautioned expert Dr. Susan Jebb.
This pace of regain means a return to original weight in about a year and a half.
Weighing Approaches
The research, which looked at 37 of studies involving thousands of patients, contrasted the results of these new drugs with other pills.
Researchers note that people who shed pounds through diet and exercise generally experience a more gradual weight regain—perhaps 0.1 kg a month—once they finish.
Explaining the Quick Rebound
Experts suggest the way of the jabs accounts for the amplified regain.
GLP-1 drugs copy a natural hormone called GLP-1, which moderates appetite.
"Artificially providing the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement leads to appetite is unsuppressed, making excessive eating far more likely."
A Chronic Condition?
Health authorities advise the injections for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts say that, due to the likelihood of relapse, the treatment might need to be long-term.
This view is echoed by drug manufacturers, who note that the results "highlight the long-term nature of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
Users who have come off the medication describe a sudden return of appetite.
"I experienced something activating and you become extremely hungry," said one woman.
The struggle is exacerbated if patients have not adopted permanent dietary or behavioural changes during treatment.
Widespread Use
Survey data show that a significant number of adults in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.
- Adoption is greater among females than men.
- The 40s and 50s demographic shows the highest usage rates.
- Many access the drugs through private prescriptions rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are powerful agents for weight loss, they are not a permanent fix and long-term success hinges on combined lifestyle support.
